A Translational In Vivo and In Vitro Metabolomic Study Reveals Altered Metabolic Pathways in Red Blood Cells of Type 2 Diabetes
Palomino-Schätzlein, Martina (Centro de Investigación Príncipe Felipe (València))
Lamas-Domingo, Rubén (Centro de Investigación Príncipe Felipe (València))
Ciudin, Andreea (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas)
Gutiérrez-Carcedo, Patricia (Hospital Universitari Vall d'Hebron)
Marés, Roso (Hospital Universitari Vall d'Hebron)
Aparicio-Gómez, Carolina (Hospital Universitari Vall d'Hebron)
Hernández, Cristina (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas)
Simó Canonge, Rafael (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas)
Herance, José Raul (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas)
Universitat Autònoma de Barcelona

Fecha:	2020
Resumen:	Clinical parameters used in type 2 diabetes mellitus (T2D) diagnosis and monitoring such as glycosylated haemoglobin (HbA1c) are often unable to capture important information related to diabetic control and chronic complications. In order to search for additional biomarkers, we performed a pilot study comparing T2D patients with healthy controls matched by age, gender, and weight. By using 1 H-nuclear magnetic resonance (NMR) based metabolomics profiling of red blood cells (RBCs), we found that the metabolic signature of RBCs in T2D subjects differed significantly from non-diabetic controls. Affected metabolites included glutathione, 2,3-bisphophoglycerate, inosinic acid, lactate, 6-phosphogluconate, creatine and adenosine triphosphate (ATP) and several amino acids such as leucine, glycine, alanine, lysine, aspartate, phenylalanine and tyrosine. These results were validated by an independent cohort of T2D and control patients. An analysis of the pathways in which these metabolites were involved showed that energetic and redox metabolism in RBCs were altered in T2D, as well as metabolites transported by RBCs. Taken together, our results revealed that the metabolic profile of RBCs can discriminate healthy controls from T2D patients. Further research is needed to determine whether metabolic fingerprint in RBC could be useful to complement the information obtained from HbA1c and glycemic variability as well as its potential role in the diabetes management.
Ayudas:	Instituto de Salud Carlos III PI16/0206 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR130
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Erythrocytes ; Type 2 diabetes mellitus ; NMR ; Metabolomics ; Biomarker
Publicado en:	Journal of clinical medicine, Vol. 9 (may 2020) , ISSN 2077-0383

DOI: 10.3390/jcm9061619
PMID: 32471219

18 p, 2.5 MB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados